



Figure S3. Kaplan–Meier survival curves of patients with CIMP-positive and -negative high-grade (grades 3 and 4) and high-stage (stages III and IV) clear cell renal cell carcinomas (ccRCCs) in the validation cohort. The cancer-free (Panel **A**, $P=1.01 \times 10^{-3}$) and overall (Panel **B**, $P=7.04 \times 10^{-4}$) survival rates of patients with CIMP-positive grade 3/4 ccRCCs were significantly lower than those of patients with CIMP-negative grade 3/4 ccRCCs (log-rank test). The cancer-free (Panel **C**, $P=7.76 \times 10^{-4}$) and overall (Panel **D**, $P=5.48 \times 10^{-5}$) survival rates of patients with CIMP-positive stage III/IV ccRCCs were significantly lower than those of patients with CIMP-negative stage III/IV ccRCCs (log-rank test). Patients who underwent curative resection are included in panels **A** and **C**.